<DOC>
	<DOCNO>NCT01301092</DOCNO>
	<brief_summary>LY2189265 investigational drug develop treatment type 2 diabetes mellitus . This study compare concentration LY2189265 use different method administration : subcutaneous ( SC- injection skin ) , intravenous ( IV - vein arm ) intramuscular ( IM - muscle leave thigh ) . The purpose study look much drug get blood stream long take body get rid give method . The study divide three part , Part A , B C. Volunteers able participate one part . All Participants Part A receive single IV dose 0.1 milligram ( mg ) . Participants Part B give drug twice IV SC injection ( 1.5 mg ) . Part B study occur Part A dose IV drug depend result Part A . Part B study may occur volunteer Part A tolerate drug . Participants Part C also give drug twice SC injection IM injection , dose 0.75 mg .</brief_summary>
	<brief_title>A Study Compare Concentrations LY2189265 After Different Methods Administration Healthy Volunteers .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<criteria>Are overtly healthy male female , determine medical history physical examination . Male subject female partner childbearing potential , partner pregnant breastfeeding , agree use reliable method contraception time first dose 3 month last dose investigational product , determine investigator . The method may one following : condom spermicidal agent , male subject sterilization , true abstinence ( line subject 's usual lifestyle choice ; withdrawal calendar method consider acceptable ) . Female subject childbearing potential ( , postmenopausal permanently sterilize [ example , tubal occlusion , hysterectomy , bilateral salpingectomy ] ) . Such subject require use contraception must test negative pregnancy time enrollment . Postmenopausal define least 1 year post cessation menses ( without alternative medical cause ) follicle stimulate hormone ( FSH ) great equal 40 milliinternational unit per milliliter ( mIU/mL ) . Female subject undergone sterilization tubal ligation : agree use condom conjunction spermicidal gel , foam , cream , film suppository time screen 3 month last dose investigational product . Such subject must also test negative pregnancy time enrollment . Have body mass index ( BMI ) 23.0 35.0 kilogram/square meter ( kg/mÂ² ) , inclusive . Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator . Have normal sit blood pressure pulse rate determine investigator , change compatible age . Have venous access sufficient allow blood sample and/or IV administration investigational product per protocol . Are reliable willing make available duration study willing follow study procedure . Have give write informed consent approve Lilly ethical review board ( ERB ) govern site . Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device , concurrently enrol type medical research judge scientifically medically compatible study . Are woman child bear potential Have know allergy Glucagonlike peptide1 ( GLP1 ) relate compound include LY2189265 . Are persons previously complete withdrawn study study investigate LY2189265 . Have abnormality 12lead Electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study . Have history presence gastrointestinal disorder ( include pancreatitis [ history chronic pancreatitis idiopathic acute pancreatitis ] gall bladder disease ) , gastrointestinal disease impact gastric empty ( GE ) ( example , gastric bypass surgery , pyloric stenosis ) could aggravate GLP analog ( example , esophageal reflux ) . Subjects cholecystolithiasis ( removal gall stone ) , cholecystectomy ( removal gall bladder ) and/or appendectomy past sequela may include study discretion screen physician . Have history presence significant active neuropsychiatric disease Regularly use know drug abuse and/or show positive finding urinary drug screening . Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody . Show evidence hepatitis C and/or positive hepatitis C antibody . Show evidence hepatitis B and/or positive hepatitis B surface antigen . Are woman positive pregnancy test woman lactate . Use intend use overthecounter medication paracetamol within 7 day prior dose prescription medication ( exception vitamin/mineral supplement and/or hormone replacement therapy and/or thyroid replacement therapy ) within 14 day prior dose . Have donate blood 500 mL within last month . Are subject average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , ( 1 unit = 12 ounce [ oz ] 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) , unwilling stop alcohol consumption least 24 hour prior screen dose , resident clinical research unit ( CRU ) . Are subject smoke 10 cigarette per day , unwilling refrain smoking day LY2189265 administration resident . Are subject , opinion investigator , way unsuitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>